De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Hexima Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Geoffrey Kempler

Algemeen directeur

AU$109.8k

Totale compensatie

Percentage CEO-salaris	38.8%
Dienstverband CEO	1.1yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.9yrs
Gemiddelde ambtstermijn bestuur	3.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Geoffrey Kempler's beloning veranderd ten opzichte van Hexima's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$110k	AU$43k	-AU$934k

Compensatie versus markt: De totale vergoeding ($USD 76.09K ) Geoffrey } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 313.13K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Geoffrey te vergelijken met de prestaties van het bedrijf.

CEO

Geoffrey Kempler (69 yo)

1.1yrs

Tenure

AU$109,813

Compensatie

Mr. Geoffrey Paul Kempler, B.Sc. Grad. Dipp. App. Soc.Psych, serves as Chairman and Managing Director of Hexima Ltd since September 05, 2023. Mr. Kempler is Chairman of AusBiotech. He Co-Founded Alterity...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Geoffrey Kempler	MD & Chairman	1.1yrs	AU$109.81k	geen gegevens
Helen Molloy	Financial Controller	no data	AU$224.24k	geen gegevens
Marilyn Anderson	Chief Science Officer	15.3yrs	AU$48.63k	1.44% A$ 40.9k
Neil Forrester	Vice President of Business Development	no data	geen gegevens	geen gegevens
Nancy Sacco	Chief Development Officer	2.8yrs	AU$175.25k	geen gegevens
Leanne Ralph	Company Secretary	3yrs	geen gegevens	geen gegevens

2.9yrs

Gemiddelde duur

Ervaren management: Het managementteam van HXL wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Geoffrey Kempler	MD & Chairman	1.1yrs	AU$109.81k	geen gegevens
Richard Scher	Member of the Scientific Advisory Board	3.6yrs	geen gegevens	geen gegevens
Tracey Vlahovic	Member of the Scientific Advisory Board	3.6yrs	geen gegevens	geen gegevens
Phoebe Rich	Member of the Scientific Advisory Board	3.6yrs	geen gegevens	geen gegevens
Warren Joseph	Member of the Scientific Advisory Board	3.6yrs	geen gegevens	geen gegevens
Justin Yap	Non-Executive Director	6.3yrs	geen gegevens	geen gegevens
Mark Lebwohl	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Boni Elewski	Member of the Scientific Advisory Board	3.6yrs	geen gegevens	geen gegevens
Peter Foley	Member of the Scientific Advisory Board	3.6yrs	geen gegevens	geen gegevens
Shinichi Watanabe	Member of the Scientific Advisory Board	3.6yrs	geen gegevens	geen gegevens
Robert Rosen	Member of the Scientific Advisory Board	3.6yrs	geen gegevens	geen gegevens
Shari Lipner	Member of the Scientific Advisory Board	2.8yrs	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van HXL wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Hexima Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

No independent directors

Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as Director

Hexima Limited, Annual General Meeting, Nov 28, 2023

Hexima Limited Appoints Phillip Hains as A Non-Executive Director

Insider recently bought AU$155k worth of stock

Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director

Recent updates

Hexima Limited has filed a Follow-on Equity Offering in the amount of AUD 7.5 million.

Real Thing Entertainment agreed to acquire Hexima Limited (ASX:HXL) in a reverse merger transaction for AUD 8.1 million.

No independent directors

Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as Director

Hexima Limited, Annual General Meeting, Nov 28, 2023

Hexima Limited Appoints Phillip Hains as A Non-Executive Director

Full year 2023 earnings released: AU$0.011 loss per share (vs AU$0.066 loss in FY 2022)

New minor risk - Financial data availability

Insider recently bought AU$155k worth of stock

Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.029 loss in 1H 2022)

Nicole Van Der Weerden to Step Down as CEO of Hexima Limited

Hexima Limited, Annual General Meeting, Jan 31, 2023

Hexima Limited Announces Board Changes

Less than half of directors are independent

Hexima Limited, Annual General Meeting, Nov 16, 2022

Full year 2022 earnings released: AU$0.066 loss per share (vs AU$0.061 loss in FY 2021)

Hexima Limited Announces Management Changes

Hexima Limited Announces Phase II Results of Pezadeftide

Hexima Limited Announces Preliminary Results of Phase II Clinical Study of Pezadeftide

Less than half of directors are independent

Is Hexima (ASX:HXL) In A Good Position To Invest In Growth?

Here's Why We're A Bit Worried About Hexima's (ASX:HXL) Cash Burn Situation

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Full year 2021 earnings released: AU$0.061 loss per share (vs AU$0.028 loss in FY 2020)

Hexima Limited Extends Its Patent Protection for Pezadeftide

Hexima Limited to Present Clinical Data from its Phase I/IIa Clinical Trial of HXP 124 for the Treatment of Onychomycosis at American Podiatric Medical Association Annual Conference

Read This Before Selling Hexima Limited (ASX:HXL) Shares

Hexima Limited Updates Timeline to Phase 2B Results

Hexima Limited has completed an IPO in the amount of AUD 3.280771 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur